Caribou Biosciences Provides Business Update and Reports Second Quarter 2021 Financial Results
September 02, 2021 16:05 ET
|
Caribou Biosciences, Inc.
Completed upsized initial public offering of common stock, raising $349.6 million in gross proceeds including full exercise of underwriters’ option to purchase additional shares ANTLER Phase 1...
Caribou Biosciences Announces Publication of Data Demonstrating High Specificity Genome Editing with its Proprietary chRDNA Technology
September 02, 2021 16:05 ET
|
Caribou Biosciences, Inc.
Data published in Molecular Cell provide a mechanistic framework to explain the enhanced specificity and key differentiation of Caribou’s proprietary chRDNA technology for therapeutic applications ...
Caribou Biosciences to Participate in Citi’s 16Th Annual BioPharma Virtual Conference
September 01, 2021 08:00 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel...
Caribou Biosciences Appoints Nancy Whiting, Pharm.D., to its Board of Directors
August 25, 2021 16:00 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that it has...